Clinical Trial Update: Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction [Phase 2]

View source ↗

Summary

A Phase 2 trial of pegamotecan for gastric and gastroesophageal junction cancers was terminated; the update does not include reported efficacy results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Pegamotecan (pegamotecan)

Snippet

Sponsor: Enzon Pharmaceuticals, Inc. | Conditions: Cancer of Stomach, Gastroesophageal Cancer | Phase 2 | Status: TERMINATED